CymaBay Therapeutics, Inc.
CBAY · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $31 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $30 | -$1 | -$1 | -$1 |
| % Margin | 97.8% | – | – | – |
| R&D Expenses | $80 | $68 | $65 | $36 |
| G&A Expenses | $52 | $25 | $23 | $17 |
| SG&A Expenses | $52 | $25 | $23 | $17 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $132 | $93 | $88 | $53 |
| Operating Income | -$102 | -$93 | -$88 | -$53 |
| % Margin | -327.2% | – | – | – |
| Other Income/Exp. Net | -$4 | -$13 | -$2 | $2 |
| Pre-Tax Income | -$105 | -$106 | -$90 | -$51 |
| Tax Expense | $0 | $13 | $3 | -$2 |
| Net Income | -$105 | -$119 | -$93 | -$49 |
| % Margin | -339.1% | – | – | – |
| EPS | -0.99 | -1.35 | -1.3 | -0.71 |
| % Growth | 26.7% | -3.8% | -83.1% | – |
| EPS Diluted | -0.99 | -1.35 | -1.3 | -0.71 |
| Weighted Avg Shares Out | 106 | 88 | 71 | 69 |
| Weighted Avg Shares Out Dil | 106 | 88 | 71 | 69 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13 | $2 | $0 | $2 |
| Interest Expense | $19 | $15 | $3 | $0 |
| Depreciation & Amortization | $1 | $2 | $1 | -$1 |
| EBITDA | -$86 | -$92 | -$87 | -$50 |
| % Margin | -275.9% | – | – | – |